188 related articles for article (PubMed ID: 33505698)
21. Risk Factors for Recurrence of Clostridioides difficile in Hospitalized Patients.
Alrahmany D; Ereshefsky BJ; El Nekidy WS; Harb G; Pontiggia L; Ghazi IM
J Infect Public Health; 2021 Nov; 14(11):1642-1649. PubMed ID: 34627059
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study.
Zilberberg MD; Reske K; Olsen M; Yan Y; Dubberke ER
BMC Infect Dis; 2014 Jun; 14():306. PubMed ID: 24898123
[TBL] [Abstract][Full Text] [Related]
23. Trends in Diverting Loop Ileostomy vs Total Abdominal Colectomy as Surgical Management for Clostridium difficile Colitis.
Juo YY; Sanaiha Y; Jabaji Z; Benharash P
JAMA Surg; 2019 Oct; 154(10):899-906. PubMed ID: 31268492
[TBL] [Abstract][Full Text] [Related]
24. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
25. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.
Zhang D; Prabhu VS; Marcella SW
Clin Infect Dis; 2018 Apr; 66(9):1326-1332. PubMed ID: 29360950
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of a Multidisciplinary Clinic in Evaluating Recurrent
Shin JH; Chaplin AS; Hays RA; Kolling GL; Vance S; Guerrant RL; Archbald-Pannone L; Warren CA
J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31315214
[TBL] [Abstract][Full Text] [Related]
27. Novel risk factors for recurrent Clostridium difficile infection in children.
Nicholson MR; Thomsen IP; Slaughter JC; Creech CB; Edwards KM
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):18-22. PubMed ID: 25199038
[TBL] [Abstract][Full Text] [Related]
28. Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent
Šamadan L; Jeličić M; Vince A; Papić N
Antibiotics (Basel); 2021 Jun; 10(7):. PubMed ID: 34198964
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Recurrent
Azimirad M; Yadegar A; Gholami F; Shahrokh S; Asadzadeh Aghdaei H; Ianiro G; Suzuki H; Cammarota G; Zali MR
J Inflamm Res; 2020; 13():563-570. PubMed ID: 32982371
[TBL] [Abstract][Full Text] [Related]
30. Investigational Treatment Agents for Recurrent
Kullar R; Tran MN; Goldstein EJC
J Exp Pharmacol; 2020; 12():371-384. PubMed ID: 33116952
[No Abstract] [Full Text] [Related]
31. Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
Huang AM; Marini BL; Frame D; Aronoff DM; Nagel JL
Transpl Infect Dis; 2014 Oct; 16(5):744-50. PubMed ID: 25040545
[TBL] [Abstract][Full Text] [Related]
32. External validation of two prediction tools for patients at risk for recurrent
van Rossen TM; van Dijk LJ; Heymans MW; Dekkers OM; Vandenbroucke-Grauls CMJE; van Beurden YH
Therap Adv Gastroenterol; 2021; 14():1756284820977385. PubMed ID: 33456500
[TBL] [Abstract][Full Text] [Related]
33. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial.
Kao D; Wong K; Franz R; Cochrane K; Sherriff K; Chui L; Lloyd C; Roach B; Bai AD; Petrof EO; Allen-Vercoe E
Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):282-291. PubMed ID: 33631102
[TBL] [Abstract][Full Text] [Related]
34. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
35. Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life.
Hengel RL; Schroeder CP; Jo J; Ritter TE; Nathan RV; Gonzales-Luna AJ; Obi EN; Dillon RJ; Van Anglen LJ; Garey KW
J Patient Rep Outcomes; 2022 May; 6(1):49. PubMed ID: 35567724
[TBL] [Abstract][Full Text] [Related]
36. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
Goldstein EJC; Citron DM; Gerding DN; Wilcox MH; Gabryelski L; Pedley A; Zeng Z; Dorr MB
Clin Infect Dis; 2020 Aug; 71(4):1102-1105. PubMed ID: 31883370
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection.
Perler BK; Chen B; Phelps E; Allegretti JR; Fischer M; Ganapini V; Krajiceck E; Kumar V; Marcus J; Nativ L; Kelly CR
J Clin Gastroenterol; 2020 Sep; 54(8):701-706. PubMed ID: 32011405
[TBL] [Abstract][Full Text] [Related]
38. Diverting loop ileostomy versus total abdominal colectomy for clostridioides difficile colitis: outcomes beyond the index admission.
Abou-Khalil M; Garfinkle R; Alqahtani M; Morin N; Vasilevsky CA; Boutros M
Surg Endosc; 2021 Jun; 35(6):3147-3153. PubMed ID: 32601762
[TBL] [Abstract][Full Text] [Related]
39. Microbiota in
Gazzola A; Panelli S; Corbella M; Merla C; Comandatore F; De Silvestri A; Piralla A; Zuccaro V; Bandi C; Marone P; Cambieri P
Biomedicines; 2020 Sep; 8(9):. PubMed ID: 32911854
[No Abstract] [Full Text] [Related]
40. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.
Wilcox MH; Ahir H; Coia JE; Dodgson A; Hopkins S; Llewelyn MJ; Settle C; Mclain-Smith S; Marcella SW
J Antimicrob Chemother; 2017 Sep; 72(9):2647-2656. PubMed ID: 28633368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
